Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Total 13F shares
-
67,974,787
-
Share change
-
+870,211
-
Total reported value
-
$2,304,237,493
-
Put/Call ratio
-
81%
-
Price per share
-
$33.93
-
Number of holders
-
164
-
Value change
-
+$32,399,854
-
Number of buys
-
68
-
Number of sells
-
93
Institutional Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q1 2021
As of 31 Mar 2021 Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) had 164 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 67,974,787 shares of stock of the company.
Largest 10 holders included FMR LLC, VANGUARD GROUP INC, WASATCH ADVISORS INC, BlackRock Inc., Bellevue Group AG, MARSHALL WACE, LLP, LORD, ABBETT & CO. LLC, CITADEL ADVISORS LLC, STATE STREET CORP, and SAMLYN CAPITAL, LLC.
This table shows 164 institutional shareholders of the security as of 31 Mar 2021.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.